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Many vaccine preventable diseases require a booster dose in addition to the primary
vaccination in order to provide adequate level of protection. However, the optimal
timing of booster dose after primary vaccination is often difficult to determine.
Here we propose an agent-based modelling framework to investigate the timing of
booster vaccination, based on the efficacy of primary vaccine series and the coverage
of booster dose. We show that these factors can significantly affect the long-term
epidemological outcomes of vaccination. We represent our results by simulating
the model for the dynamics of Heamophilus influenzae serotype b (Hib), using
parameter estimates for natural history of the disease, its transmissibility, and
the protection efficacy of vaccine. We show that, for estimated vaccine protection
efficacy against Hib, if the primary and booster coverages are maintained at high
levels, a longer time interval between primary and booster doses leads to better
outcomes and potentially elimination of the disease. The length of this time interval
is however dependent on the coverage of booster vaccination.
1. Introduction
Vaccination remains the most successful preventive measure against many
infectious diseases in modern medicine1. Despite successful implementation
of vaccination programs, elimination of some disease has proven challenging,
with instances of resurgence occurring in different geographic locations2,3,4.
Several factors have been investigated as potential explicators for persis-
tence and recurrent outbreaks of vaccine-preventable diseases, including
incomplete protection efficacy of primary series, inadequate coverage of
booster doses, waning immunity over time, and the period of vaccine-
induced protection that may be significantly shorter than the average life-
time of the population5,4. However, given these factors, the time interval
between primary series and booster vaccination may significantly influence
both short- and long-term disease outcomes.
In this study, we develop an agent-based modelling (ABM) framework
to investigate how the interval between primary and booster vaccination
affects disease dynamics. While importance of age at vaccination has
been well documented, the optimal timing of booster doses remains un-
clear in several vaccine-preventable diseases6,7,4. For this study, we con-
sidered Haemophilus influenzae serotype b (Hib), for which primary and
booster vaccination has been implemented in routine infant immunization
programs in many countries. Yet, the elimination has not been achieved,
notwithstanding substantial levels of routine primary vaccine series2,3,4.
We included key biological and epidemiological determinants of Hib in the
model, and parameterize it with the previously published estimates to in-
vestigate the effect of timing for booster dose after primary vaccination on
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Figure 1. Age distribution of the United Kingdom population according to the 2011
census data: https://en.wikipedia.org/wiki/Demography_of_the_United_Kingdom.
the prevalence of disease. We illustrate our results using stochastic Monte-
Carlo simulations, and argue that the timing of booster dose may be an
essential component of vaccination programs, whose optimal determination
depends critically on the protection efficacy of primary vaccine series, and
the coverage of booster vaccination.
2. Methodology
2.1. Agents-environment framework
The general framework of the model includes two main entities: (i) a sim-
ulated environment represented by a two dimensional lattice and (ii) the
individuals that are located in the lattice. Each individual is characterized
by their time-sensitive information vector, which encapsulates a plethora
of information including the current health status, age, and the immune
protection level. The size of the lattice was set to 317×317, resulting in an
environment with 100489 individuals with age distributions similar to the
UK population (Figure 1). The interaction between individuals was mod-
elled through contacts with their immediate neighbours or random contacts
on the lattice.
2.2. Disease model
In construction of the ABM framework, we consider the disease model
with several epidemiological statuses of the individuals, based on which
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Figure 2. Schematic model diagram for transitions between epidemiological compart-
ments in the disease model of the ABM framework.
the population is divided into several compartments. The disease model
includes compartments of susceptible (S), primary latent (L1), secondary
latent (L2), pre-symptomatic (P ), asymptomatic referred to as carriage
(C), symptomatic (I), invasive disease (Iv), recovered (R), vaccinated with
primary series (V1), vaccinated with booster dose (V2), partially protected
stage 1 (W1), and partially protected stage 2 (W2). Disease transmission
occurs as a result of contact between infectious individuals (either in car-
riage of symptomatic stages), and those with no or incomplete protection
(i.e., susceptible or partially protected individuals). The movements of
individuals between the epidemiological compartments of the model are
schematically represented in Figure 2.
Once exposed to the disease with successful transmission, the individu-
als will enter one of the latent stages (primary or secondary), depending on
whether or not they have any protection level as a result of previous natural
infection or vaccination. Individuals in the latent stages are assumed to be
non-infectious and therefore cannot transmit the disease. Infected individu-
als with no pre-existing immune protection will proceed to pre-symptomatic
infection and develop either symptomatic disease (with clinical manifesta-
tion) or remain asymptomatic (without clinical symptoms) for the entire
duration of infectious period. If treatment is not sought, symptomatic in-
dividuals may develop invasive disease with potentially fatal outcomes. We
assumed that infected individuals with pre-existing immune protection will
develop only asymptomatic disease and remain carriage. Following recov-
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ery from infection, individuals will have a fixed period of full protection,
during which no infection can occur. We also assumed this immune protec-
tion wanes over time and once the period of full protection has elapsed, the
individuals will have a fixed period of partial protection, during which the
infection can occur, albeit with lower transmission probability compared to
fully susceptible individuals. This is followed by a second period of partial
protection, sampled for each individual independently, with a lower pro-
tection level compared to the first period of partial protection. After the
second protection period has elapsed, individuals will become susceptible
to the disease again.
2.3. Vaccination model
For evaluating the effect of vaccination, we implemented primary vaccina-
tion for infants within their 6 months of birth8. Booster vaccination was
offered only to those who had received primary vaccination. Vaccination of
infants with primary series will lead to a fixed duration of partial protec-
tion, and followed by the second period of partial protection (as described
above for natural infection) without booster vaccination. Those who re-
ceived booster vaccination will be fully protected for a fixed length of time,
and follow the same path of partial protection as described for individuals
recovered from natural infection.
2.4. Computational implementation
The model was calibrated with the reproduction number R0 = 1.3
9 to ob-
tained the baseline transmissibility β = 7 × 10−3 in the absence of any
interventions (i.e., treatment or vaccination). Simulations were initialized
with C(0) = 15 for infection. The parameters governing the dynamics of
the model were drawn from previously published literature, and are de-
scribed in Table 1. The model includes both disease induced and natural
deaths. All deaths were replaced with newborns, thus maintaining a con-
stant population size. The probability of natural death was calculated from
its associated distribution with the median life expectancy of 60 years.
The success of transmission was determined using rejection sampling-
based (Bernoulli) trials where the chance of success is defined by a trans-
mission probability distribution. In the absence of pre-existing immune
protection, the spread of disease between a susceptible-infectious pair of
individuals was calculated using the baseline transmission probability
P0 = 1− (1− ηpβ)Kp(1 − ηcβ)Kc(1− β)Ks (1)
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where Kp is the number of contacts with pre-symptomatic individuals, Kc
is the number of contacts with individuals in the stage of carriage, Ks is
the number of contacts with symptomatic individuals, and ηp and ηc are
respectively the relative reduction of infectiousness in pre-symptomatic and
carriage individuals compared with symptomatic individuals. However, the
probability P0 is subject to the immune protection level of the individuals.
To account for the effect of immunity in the reduction of disease transmis-
sibility, we calculated the transmission probability by
PV1 = (1− ηv1)P0 (2)
for primary vaccinated individuals, and by
PW1 = (1− ηw1)P0,
PW2 = (1− ηw2)P0,
(3)
for individuals in the first and second stages of partial protection, where
ηv1 , ηw1 , and ηw2 are respectively the relative reductions of susceptibil-
ity to infection (as a results of immune protection) compared with fully
susceptible individuals.
2.5. Parmeterization and timing of booster vaccination
We parameterize the model with estimates for various epidemiological stage
and duration of protection induced by vaccination or natural infection.
These parameters and their sources are provided in Table 1. A number
of parameters were varied in our simulations to evaluate the effect of the
primary vaccine series and the subsequent booster dose. The timing for
booster dose was varied between 6 to 48 months after primary vaccination.
We assumed three different profiles of booster dose coverage (Figure 3): (i)
a fixed coverage the same as the primary vaccine coverage regardless of the
time for booster dose (Figure 3, dark grey bars); (ii) a reduced coverage of
booster that follows an exponential declining trend (Figure 3, black bars);
and (iii) a reduced coverage of booster that follows a declining trend similar
to the inverse of the logistic function (Figure 3, light grey bars). The re-
duction in booster dose coverage may reflect a number of factors, including
higher rates of refusal to receive additional vaccine doses following primary
series, which may be affected by delay in booster schedule.
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Table 1. Description of model parameters and their associated values (ranges) extracted
from the published literature.
parameter description value (range) source
basic reproduction number 1.3 (1.1− 1.5) 10,11
coverage of primary vaccination 0.95 (0− 1) –
coverage of booster vaccination variable (0− 1) –
latent period 2 (1–3) day 12
pre-symptomatic period 1.5 (1–2) days 12
infectious period of carriage and 14–70 days 12,13,2
symptomatic infection
age at completion of primary vaccine series 6 months 8
timing of booster coverage post variable (0–48) months –
primary vaccination
ﬁxed period of full protection following 2 years 12,2
recovery from infection
ﬁxed period of full protection following 6 years 12,2,9,13
booster vaccination
ﬁxed period of partial protection stage 1 2 years 12
period of partial protection stage 2 2–8 years 12
level of immune protection following 0.8 (0.6–0.9) 12,2,9,13
primary vaccination
level of immune protection during 0.6 (0.3–0.9) 12,2
partial protection stage 1
level of immune protection during 0.3 (0.1–0.5) 12,2
partial protection stage 2
infectious period following start of treatment 2 days ?,12
in symptomatic infections
probability of developing carriage without 0.6–0.9 12,13
pre-existing immune protection
3. Results
For each scenario of booster dose coverage (Figure 3), we ran stochastic
simulations to obtain the average of 100 independent realizations. The
model with vaccination was seeded with the initial conditions given by the
components of the endemic equilibrium of the model without vaccination.
For the scenarios simulated here, the timing for booster dose after primary
vaccination was varied. Figure 4 shows the prevalence of carriage for 28
years following the start of vaccination, when the booster dose was oﬀered
with delay of 9 months, 24 months, or 36 months after primary vaccination.
For all scenarios, the introduction of vaccination signiﬁcantly reduced the
prevalence of carriage in the absence of vaccination.
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Figure 3. Time-dependent coverage of booster vaccination post primary vaccination.
When the booster dose coverage is maintained at 95% (Figure 4A),
we observed minimal differences with increasing delay in booster vaccina-
tion, with slight advantage in booster vaccination with longer delay (36
months). However, for a booster coverage that declines exponentially with
delay (Figure 4B), we observed that early booster (9 months) outperforms
other strategies with longer delays, contrasting the scenario of fixed booster
coverage. As delay in timing of booster dose increases, a lower fraction of
primary vaccinated individuals receives booster dose which leads to a higher
prevalence of infection over time. For the scenario in which the coverage of
booster dose reduces over time similar to the inverse of the logistic function
(Figure 3), both strategies of early (9 months) and late (36 months) booster
vaccination were outperformed by the strategy with an intermediate delay
of 24 months. These results suggest that timing of booster vaccination
could have a significant impact on the long-term disease outcomes, and the
optimal timing depends not only on the protection efficacy of the vaccine,
but also on the coverage of the booster dose.
4. Concluding Remarks
There is evidence accumulating that the booster vaccine schedule requires
evaluation for several vaccine-preventable diseases to improve the effect of
vaccination campaigns6,7,4. Previous studies have shown the time interval
between the primary vaccination and booster dose could play a vital role
in the long-term dynamics of Hib14, and a large delay in booster vaccina-
tion may result in a longer protection period during lifetime15. However, a
larger delay may lead to a lower fraction of primaries receiving the booster
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dose as a results of parental hesitancy and refusal with subsequent increase
in the number of unvaccinated and undervaccinated individuals16,17,18.
In this study, we developed an agent-based model of disease transmis-
sion to investigate the vaccination and timing of booster dose on the preva-
lence of long-term infection dynamics. Considering several biological and
epidemiological aspects of natural and vaccine-induced immunity, we sim-
ulated the model for various delays in booster dose vaccination using pa-
rameter values estimated for Heamophilus influenza serotype b published
in the literature.
Simulation results indicate that the timing of booster dose can signif-
icantly influence the prevalence of infection in the population. While we
compared the outcomes of different strategies for booster schedule, determi-
nation of the optimal timing for booster vaccination remains a challenging
task. Although we have shown in a number of scenarios simulated here
that the delay in booster vaccination may be beneficial in reducing the dis-
ease prevalence, the coverage of booster remains a key determining factor
that may be influenced by the delay in booster vaccination16,17,18. If the
coverage of booster vaccination is expected to drop significantly over time,
our simulations illustrate that early booster schedule may be essential to
achieve the greatest reduction of the disease prevalence.
The objective of this study was not to determine the optimal timing of
a booster dose vaccination, but rather illustrate the complexity of the dis-
ease dynamics in the context of vaccination and highlight the challenge in
optimizing immunization programs with long-lasting effects in prevention
and disease elimination.
The model proposed here could be further evaluated with variability
is parameter space to better understand the sensitivity of outcomes with
respect to the infection and vaccination specific parameters. This under-
standing could help to more accurately quantify the benefit of different
vaccination programs and booster schedules.
 
M
at
he
m
at
ic
al
 B
io
lo
gy
 a
nd
 B
io
lo
gi
ca
l P
hy
sic
s D
ow
nl
oa
de
d 
fro
m
 w
w
w
.w
or
ld
sc
ie
nt
ifi
c.
co
m
by
 U
N
IV
ER
SI
TY
 O
F 
M
IC
H
IG
A
N
 A
N
N
 A
RB
O
R 
on
 0
8/
04
/1
7.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
April 25, 2017 15:6 BIOMAT 2016 04 page 69
69
       	 

ï
ï




       	 

ï
ï




       	 

ï




in
ci
d
en
ce
 o
f c
ar
ria
g
e
time (years post vaccination)
(A)
(B)
(C)
Figure 4. Incidence of carriage with three different booster vaccination coverage scenar-
ios: (A) Fixed (95%) coverage; (B) declining coverage similar to the inverse of logistic
function; and (C) exponentially declining coverage (as illustrated in Figure 3). Delay in
booster dose is 9 months (bold black curves), 24 months (gray curves), and 36 months
(black curve).
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